An interventional study of Energy-Restricted Diet and Whole-Body Electromyostimulation (WB-EMS) in Obesity & Overweight, Metabolic Disorders and Electrotherapy, sponsored by Firat University. Not yet recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Firat University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.
Among the 353 studies in Obesity with a site in Turkey, this one is the 141st largest by planned enrollment of the 192 interventional ones that give a count, is one of 60 that started in 2026, is one of 161 with no phase, reaches primary completion later than 51 of the 89 other live ones, and was the 278th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Gazi University · Sites in Turkey
Ages 50–60 · Women only
Duzce University · Sites in Turkey
Ages 18+
Pamukkale University · Sites in Turkey
Ages 18–60 · Women only
Kocaeli University · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 27 · Phase 4 3
First in 2005; this study’s year is marked. 60 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 64 across the 192 interventional studies, 82 across the 160 observational. Of the 237 that completed or were terminated, 7 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 353 have an industry lead sponsor. The 10 most frequent:
Firat University is the lead sponsor of 119 studies on the registry; 45 are open to participants now.
Firat University has 5 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07769736Istinye UniversityMotivational Interviews Based on the Five-Step (5A) Model on Obesity Risk | 2026-11 |
| NCT07652151Fundación Pública Andaluza para la gestión de la Investigación en SevillaUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers | 2026-11 |
| NCT07846956Istanbul Saglik Bilimleri UniversityNAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | 2026-11-30 |
| NCT07858864Istanbul Saglik Bilimleri UniversityGLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 353 studies in Obesity with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity is a major global health problem associated with metabolic dysfunction, altered adipokine signaling, and impaired appetite regulation. Conventional weight loss strategies such as calorie restriction often result in compensatory physiological adaptations, including increased appetite and loss of lean body mass, which may limit long-term effectiveness.
Whole-body electromyostimulation (WB-EMS) is an emerging, time-efficient intervention that induces simultaneous muscle activation and may improve metabolic health. However, the underlying molecular mechanisms, particularly the interaction between myokines and adipokines, remain insufficiently understood.
This randomized controlled trial aims to investigate the effects of an energy-restricted diet combined with WB-EMS on myokine-adipokine interaction, appetite regulation, and body composition in obese individuals. Participants will be randomly assigned to either a diet-only group or a diet plus WB-EMS group for 8 weeks.
Primary outcomes include changes in serum irisin levels. Secondary outcomes include myostatin, leptin, adiponectin, FGF-21, ghrelin, GLP-1, body composition parameters, and eating behavior. The findings of this study are expected to provide novel insights into the physiological and molecular effects of WB-EMS as a complementary strategy in obesity management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive an individualized energy-restricted diet program.
Behavioral: Energy-Restricted Diet
Participants receive an energy-restricted diet combined with whole-body electromyostimulation (WB-EMS).
Behavioral: Energy-Restricted Diet · Device: Whole-Body Electromyostimulation (WB-EMS)
A personalized diet with approximately 750 kcal/day energy deficit.
Whole-body electromyostimulation applied 2-3 times per week for 8 weeks under supervision.
Change in serum irisin levels
Assessment of change in circulating irisin levels measured by ELISA.
Time frame: Baseline to 8 weeks
Change in serum myostatin levels
Assessment of change in circulating myostatin levels measured by ELISA.
Time frame: Baseline to 8 weeks
Change in serum leptin levels
Assessment of change in circulating leptin levels.
Time frame: Baseline to 8 weeks
Change in serum adiponectin levels
Assessment of change in circulating adiponectin levels.
Time frame: Baseline to 8 weeks
Change in serum FGF-21 levels
Assessment of change in circulating fibroblast growth factor-21 levels.
Time frame: Baseline to 8 weeks
Change in serum ghrelin levels
Assessment of change in circulating ghrelin levels.
Time frame: Baseline to 8 weeks
Change in serum GLP-1 levels
Assessment of change in circulating GLP-1 levels.
Time frame: Baseline to 8 weeks
Change in fat mass
Assessment of change in total body fat mass measured by bioelectrical impedance analysis (BIA).
Time frame: Baseline to 8 weeks
Change in fat-free mass
Assessment of change in fat-free mass measured by bioelectrical impedance analysis (BIA).
Time frame: Baseline to 8 weeks
Change in body fat percentage
Assessment of change in body fat percentage measured by bioelectrical impedance analysis (BIA).
Time frame: Baseline to 8 weeks
Change in eating behavior scores
Assessment of eating behavior using the Three-Factor Eating Questionnaire-Revised 21 (TFEQ-R21). The questionnaire evaluates cognitive restraint, uncontrolled eating, and emotional eating behaviors. Scores range from 21 to 84, with higher scores indicating more problematic eating behaviors.
Time frame: Baseline to 8 weeks
Plan to share: No — Individual participant data will not be shared due to privacy, ethical, and data protection considerations. The dataset contains sensitive clinical and biochemical information, and sharing is restricted to ensure participant confidentiality in accordance with institutional policies and applicable regulations.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.